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OBJECTIVES To determine the effect of macrophage colony–stimulating factor (MCSF) on atherogenesis
in patients with coronary artery disease (CAD), we assessed the relation between the plasma
concentration of MCSF and the incidence of acute coronary events in patients with CAD.
BACKGROUND Cytokines such as MCSF play a central role in inflammatory and proliferative responses in
patients with acute coronary syndromes. However, the effect of MCSF on the clinical course
in patients with CAD is still not known.
METHODS We measured the plasma MCSF concentration in 142 patients with documented CAD (62 6
9 years) and followed up for a mean period of 14 6 6 months. The study included 97 patients
with stable angina (SA), 45 patients with unstable angina (UA) and 22 age-matched control
subjects. The predictors of coronary events were analyzed by using a Cox proportional hazards
model.
RESULTS The mean plasma MCSF concentration in patients with UA was significantly higher than
that in patients with SA and in control subjects (981 6 277 vs. 693 6 223 vs. 680 6
158 pg/ml, p , 0.001). The mean plasma MCSF concentration in the 20 patients with
coronary events was significantly higher than that in patients without coronary events
(1,192 6 232 vs. 690 6 213 pg/ml, p , 0.001). The predictors of unfavorable outcome were
an increased MCSF concentration, the presence of CAD and a low ejection fraction.
CONCLUSIONS These findings suggest that an increased circulating MCSF concentration reflects atheroscle-
rotic progression in patients with CAD and predicts future cardiac events. (J Am Coll
Cardiol 2000;35:655–65) © 2000 by the American College of Cardiology
The primary function of macrophage colony–stimulating
factor (MCSF) is the regulation of the growth, differenti-
ation and maturation of monocytes and macrophages (1–3).
The expression of MCSF messenger ribonucleic acid and
the presence of MCSF protein have been demonstrated in
atherosclerotic lesions in humans (4). Further, the foam
cells from atheroma are derived primarily from macrophages
(5). The administration of MCSF in vivo has been shown to
lower plasma cholesterol concentrations rapidly in various
animal models (1,6). Based on these findings, increases in
circulating MCSF concentration may be due to increases in
the cholesterol concentration, resulting in the activation of
monocytes in the arterial wall (2,6,7). Therefore, persis-
tently elevated circulating concentrations of MCSF may
reflect active systemic atherogenesis. Furthermore, several
investigators have demonstrated that a high macrophage
content is present in samples of coronary atherosclerotic
plaque tissue from patients with acute coronary syndromes
or from patients undergoing percutaneous transluminal
coronary angioplasty (PTCA) (8–11).
Macrophages phagocytose lipids and are transformed into
foam cells. Then the macrophages release the lipids into the
necrotic center of the atherosclerotic plaque. Finally, after
the phagocytosis of the lipids, the activated macrophages
move from the lipid core to the fibrous cap, weakening the
barrier of the fibrous cap (12). The mechanism responsible
for macrophage involvement in the genesis of cardiac events
may include thrombus organization, smooth muscle cell
migration and proliferation and constrictive scarring of the
adventitia. However, the mechanism has not been clearly
established. In addition, it is unclear whether the circulating
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MCSF concentration can predict the clinical course or
prognosis of patients with coronary artery disease (CAD).
In the present study, we investigated the relation between
the incidence of acute coronary events and the plasma
concentration of circulating MCSF in patients with angina
pectoris.
METHODS
Study group. The study was approved by the Nippon
Medical School Human Ethics Committee, and written,
informed consent was obtained from all of the patients. One
hundred seventy-eight consecutive patients (137 men and
41 women, mean age 61 6 10 years) with documented
CAD by coronary arteriography were enrolled. Thirty-one
patients were excluded from the study because of the
presence of the following diseases influencing the MCSF
concentration: 1) acute myocardial infarction (13); 2)
arrhythmia (supraventricular or ventricular) or atrial
fibrillation/flutter; 3) renal dysfunction with a creatinine
concentration $133 mmol/liter or evidence of gout; 4)
neoplastic disease within the previous five years; 5) infec-
tious diseases or autoimmune diseases; 6) pregnancy; or 7)
extracardiac atherosclerotic macroangiopathy. Furthermore,
patients who had undergone coronary artery bypass graft
surgery (CABG) were excluded from the study because the
operation could trigger an increase in the plasma MCSF
concentration.
All patients were characterized according to age, gender,
history of myocardial infarction, previous revascularization
with CABG or PTCA, standard risk factor assessment and
history of angina. Patients with angina were treated with
medical therapy. Unless the angina resolved with medical
treatment, revascularization with PTCA or CABG was
performed. Patients with effort-induced angina were de-
fined by the following criteria: 1) significant coronary
stenoses by coronary arteriography (.50% diameter steno-
sis); and 2) significant ST segment depression during 24-h
Holter monitoring or treadmill exercise testing with asso-
ciated anginal chest pain. Patients with vasospastic angina
were characterized by spontaneous episodes of chest pain at
rest with accompanying ischemic ST segment elevations or
angiographic evidence of .50% vasoconstriction induced by
acetylcholine infusion in one or more segments of the
epicardial arteries with associated ischemic ST segment
elevations.
The 22 control subjects included 10 healthy volunteers
and 12 patients with atypical chest pain but without
abnormal global cardiac function, evidence of significant
coronary stenosis, diabetes mellitus, hypertension or gout.
None of the control subjects received any drugs.
Study design and assays. After an overnight fast, blood
and urine were collected for the analysis of serum lipids,
renal function and plasma glucose. The MCSF concentra-
tion and blood pressure were measured early in the morning
on the day after admission for patients with stable angina
(SA). In contrast, blood sampling in patients with unstable
angina (UA) and patients undergoing PTCA was per-
formed 7 to 10 days after hospital admission or PTCA.
Because intravenous heparin and the other intravenous
anticoagulant drugs used during the early treatment stage
for acute coronary syndromes can influence the MCSF
concentration (14), blood sampling in in-patients with UA
was performed after the stabilization of anginal attacks. Low
density lipoprotein (LDL) cholesterol, very low density
lipoprotein (VLDL) cholesterol, high density lipoprotein
(HDL) cholesterol, lipoprotein (a) and plasma MCSF
concentration were measured in patients with angina pec-
toris and in control subjects. Blood sampling in out-patients
was performed after an overnight fast. The plasma MCSF
concentration was measured using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (R & D
System Inc., Minneapolis, Minnesota). The sensitivity of
the MCSF assay was 40 pg/ml. The interassay and intra-
assay variations of the ELISA measurements were less than
5% to 10%. We assessed the following risk factors within
two weeks of the MCSF measurement: serum uric acid
concentration, plasma lipid concentration, body weight and
smoking habit.
Cardiac catheterization. A standard protocol for right-
and left-sided cardiac catheterization and coronary angiog-
raphy was performed. Significant coronary artery stenosis
was defined as $50% reduction in the luminal diameter in
the main truncus and $75% at all other sites. The left
ventricular ejection fraction (LVEF) was calculated during
left ventriculography using the modified area–length
method. Calcium antagonists and long-acting nitrates were
discontinued in patients with vasospastic angina at least
48 h before cardiac catheterization. The vasomotor response
to intracoronary acetylcholine chloride infusion (Daiichi
Pharmaceutical, Tokyo, Japan) was determined. Coronary
arteriograms were performed when acetylcholine-induced
vasospasm (.50% reduction in luminal diameter in one or
more segments of the epicardial coronary arteries) with
ischemic electrocardiographic (ECG) changes ($1 mm ST
segment depression or elevation) occurred.
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
LVEF 5 left ventricular ejection fraction
MCSF 5 macrophage colony–stimulating factor
PTCA 5 percutaneous transluminal coronary
angioplasty
SA 5 stable angina
UA 5 unstable angina
VLDL 5 very low density lipoprotein
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Follow-up. One hundred forty-seven patients with angina
pectoris met the inclusion criteria and constitute the study
group. However, five patients could not be contacted during
follow-up. Therefore, 142 patients completed the follow-up
(112 men and 30 women, mean age 62 6 9 years [range 41
to 80]). The mean follow-up period was 14 6 6 months.
Most patients returned for out-patient evaluation at
one-month intervals. Clinical assessment, including evalu-
ation of cardiac status, electrocardiography and assessment
of drug compliance, was performed at each visit. The start of
the follow-up period was the day of MCSF sampling. The
clinical end points included the occurrence of acute coronary
events: 1) cardiac death; 2) acute myocardial infarction; 3)
hospital admission for UA; 4) emergent revascularization
with PTCA or CABG because of new or worsening
symptoms; and 5) the exclusion criteria described earlier. In
the present study, the clinical end points only represented
acute coronary events, not progression of cardiac disease.
Therefore, the use of elective PTCA or CABG, which
represented therapy for progression of disease, was not
included as a clinical end point. Deaths were classified as
cardiac or noncardiac. Myocardial infarctions were con-
firmed by standard ECG criteria and increases in the serum
creatine kinase isoenzyme activity. Hospital admissions for
UA were diagnosed on the basis of worsening exertional
angina or new-onset angina with typical ischemic ECG
changes but without increases in the serum creatine kinase
activity.
The patients were monitored every six months by tread-
mill exercise testing. Those patients who underwent PTCA
at the start of the follow-up period had a second coronary
arteriogram performed at six to 12 month intervals after the
initial PTCA. Those who had silent myocardial ischemia or
anginal pain during treadmill exercise testing or who devel-
oped restenosis or a new stenotic region based on the second
coronary arteriogram without worsening angina underwent
elective PTCA or CABG. Reevaluation of the plasma
MCSF concentration in patients with acute coronary events
was performed immediately after re-admission to the hos-
pital.
Statistical analysis. All data are expressed as the mean
value 6 SD. The unpaired Student t test was used to
compare the two groups. The Levene test was used for
homogeneity of variance testing, and one-way analysis of
variance was used to assess any differences in multiple group
data. Post hoc analysis was performed with Dunnett’s test or
the Games-Howell test. The chi-square test with Yates’
correction or the Fisher exact probability test was applied for
dichotomous and categoric data. Correlations between clin-
ical variables were determined using the Spearman correla-
tion coefficient. Estimation of the cumulative probability of
event-free survival was performed with the Kaplan-Meier
method, and differences between the curves were assessed
with the Wilcoxon test. To determine the predictors of
acute coronary events, the Cox proportional hazards model
was used with the stepwise selection method. This model
was constructed using the following variables: age, gender,
body mass index, any smoking habit, history of diabetes
mellitus, history of hypertension, history of hyperuricemia,
history of previous myocardial infarction, nonuse of calcium
antagonists, nonuse of beta-blockers, nonuse of oral ni-
trates, nonuse of antiplatelet agents, nonuse of aspirin,
nonuse of lipid-lowering drugs, nonuse of angiotensin-
coverting enzyme inhibitors, plasma LDL cholesterol con-
centration, VLDL cholesterol concentration, HDL choles-
terol concentration, lipoprotein (a) concentration, plasma
MCSF concentration, extent of CAD and left LVEF. The
appropriateness of the hazard assumption was examined by
preparing log (2log) plots of the survival function. Further-
more, multivariate-adjusted risk ratios (RR) and 95% con-
fidence intervals (CI) were reported. This model influence
of profile and interaction was examined by regression
diagnosis. Two-tailed p values ,0.05 were considered
statistically significant. Statistical analyses were performed
with a computer and the Statistical Package for the Social
Sciences (SPSS, 1997) system 7.5.2J software.
RESULTS
Patient characteristics. Baseline characteristics of the
study patients are summarized in Table 1. The mean age of
the study group was 62 6 9 years (range 36 to 80). The
study included 97 patients with SA and 45 patients with
UA; 49 of the patients had a previous myocardial infarction.
Furthermore, 103 patients had exertional angina and 39
patients had vasospastic angina. The mean creatinine con-
centration in the patients with UA and SA was significantly
higher than that in the control subjects (88 6 18 vs. 88 6
18 vs. 71 6 9 mmol/liter, p , 0.001). Although there were
no significant differences in the plasma concentrations of
LDL cholesterol and lipoprotein (a) between the patients
with UA and SA and the control subjects, the plasma
concentration of HDL cholesterol in the patients with UA
and SA was significantly lower than that in the control
subjects (p , 0.001). Of the control subjects, four had a
mild degree of hyperlipidemia and four had hyperuricemia.
About one-half of the study patients had hypertension or
diabetes mellitus.
With respect to therapy, 61 patients with angina pectoris
had undergone PTCA at the start of the follow-up period,
and the incidence of PTCA between inpatients with UA
and patients with SA was similar. Further, there were no
significant differences in the frequency of the use or type of
anti-ischemic agent, aspirin or antiplatelet agents used by
the physicians between inpatients with UA and patients
with SA. However, the frequency of treatment with lipid-
lowering drugs in patients with UA was significantly lower
than that in patients with SA (p , 0.02).
With respect to coronary arteriography, 34 (92%) of 37
patients who had major epicardial coronary arteries with
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#50% diameter stenosis were diagnosed as having vasospas-
tic angina.
Circulating MCSF concentration. The mean MCSF
concentration at the start of the follow-up period in patients
with UA was significantly higher than that in patients with
SA and in control subjects (981 6 277 vs. 693 6 223 vs.
680 6 158 pg/ml, p , 0.001) (Fig. 1). The mean MCSF
concentrations in patients with zero, one, two and three
diseased coronary arteries were 689 6 248, 747 6 223,
860 6 289 and 911 6 331 pg/ml, respectively, which
indicated a significant positive correlation between the
MCSF concentration and the extent of CAD (r 5 0.328,
p , 0.001) (Fig. 2). The clinical features of the patients
with different degrees of CAD are summarized in Table 2.
Cardiac events. Twenty acute coronary events occurred
within two years of follow-up. The mean time from the
beginning of the follow-up period to coronary events was
3.8 6 2.5 months (Table 3). Of the acute coronary events,
there were seven patients with acute myocardial infarctions,
eight patients with UA requiring hospital admission and
five patients with requiring emergent PTCA or CABG.
Fifteen patients were excluded during the follow-up because
they underwent elective PTCA or CABG, and four patients
experienced cerebral ischemic accidents or arteriosclerotic
obliteration. In a multiple comparison among patients with
acute coronary events, patients with elective PTCA or
CABG, patients with other atherosclerotic events and
patients without coronary events (none in Table 3), those
with acute coronary events had a significantly higher plasma
MCSF concentration than those without coronary events
(p , 0.001). The mean plasma MCSF concentration at the
start of the follow-up period in the 15 patients who
underwent elective PTCA or CABG during follow-up was
higher than that in patients (n 5 59) without any cardiac
events and who did not receive PTCA at the start of the
Table 1. Baseline Characteristics of Study Group
Variables
Patients With Angina Pectoris
Control
Group
(n 5 22) p Value*
Total
(n 5 142)
UA
(n 5 45)
SA
(n 5 97)
Age (yrs) 62 6 9 65 6 8 61 6 9 60 6 7 0.02
Men 112 (79%) 35 (78%) 77 (79%) 15 (68%) 0.26
BMI (kg/m2) 23.3 6 2.6 23.2 6 2.7 23.4 6 2.6 22.5 6 2.9 0.39
Creatinine (mmol/liter) 88 6 18 88 6 18 88 6 18 71 6 9 ,0.001
Previous MI 49 (35%) 15 (33%) 34 (35%) 0 0.84
Plasma lipid concentration
LDL-c (mmol/liter) 3.1 6 0.9 3.2 6 1.1 3.0 6 0.7 2.9 6 0.5 0.21
HDL-c (mmol/liter) 1.2 6 0.3 1.1 6 0.3 1.2 6 0.4 1.5 6 0.2 ,0.001
Lipoprotein (a) (mg/dl) 26 6 24 32 6 31 23 6 20 23 6 15 0.09
VLDL-c (mg/dl) 207 6 123 186 6 115 226 6 121 187 6 133 0.03
Coronary risk factors
Hypertension (%) 80 (56%) 25 (56%) 55 (57%) — 0.90
Diabetes (%) 48 (34%) 14 (31%) 34 (35%) — 0.64
Hyperlipidemia (%) 96 (68%) 31 (69%) 65 (67%) 4 (18%) ,0.001
Smoking (%) 74 (52%) 24 (53%) 50 (52%) 8 (36%) 0.69
Therapy
PTCA (%) 61 (43%) 19 (42%) 42 (43%) — 0.90
Oral nitrates (%) 89 (63%) 28 (62%) 61 (63%) — 0.94
Calcium antagonists (%) 98 (69%) 34 (75%) 64 (66%) — 0.25
Beta-blockers (%) 21 (15%) 3 (7%) 18 (19%) — 0.06
ACE inhibitors (%) 50 (35%) 17 (38%) 33 (34%) — 0.66
Lipid-lowering drugs (%) 52 (37%) 10 (22%) 42 (43%) — 0.02
Aspirin (%) 64 (45%) 22 (49%) 42 (43%) — 0.53
Antiplatelet agents (%) 66 (46%) 23 (51%) 43 (44%) — 0.45
No. of diseased coronary arteries
Zero vessels (%) 37 (26%) 12 (27%) 25 (26%) — 0.01
One vessel (%) 51 (36%) 9 (20%) 42 (43%) — —
Two vessels (%) 27 (19%) 9 (20%) 18 (19%) — —
Three vessels (%) 27 (19%) 15 (33%) 12 (12%) — —
LVEF (%) 64 6 14% 62 6 17% 65 6 12% — 0.27
*Indicates statistical differences between patients with UA, those with SA and control subjects in multiple comparisons using analysis of variance. Data are presented as the mean
value 6 SD or number (%) of patients or subjects.
ACE 5 angiotensin-converting enzyme; BMI 5 body mass index; HDL-c 5 high density lipoprotein cholesterol; LDL-c 5 low density lipoprotein cholesterol; LVEF 5
left ventricular ejection fraction; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty; SA 5 stable angina; UA 5 unstable angina; VLDL-c 5
very low density lipoprotein cholesterol.
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follow-up period or in those (n 5 44) who underwent
PTCA at the start of the follow-up period and did not
experience any cardiac events (803 6 177 vs. 669 6 225 vs.
725 6 170 pg/ml, respectively).
With respect to the correlation between the degree of
CAD and the incidence of acute coronary events, three
coronary events occurred in patients with one-vessel disease,
eight in patients with two-vessel disease and nine in patients
with three-vessel disease (Table 4). There were no coronary
events in patients without CAD. Of the patients with acute
coronary events, nine patients (45%) had undergone elective
PTCA at the beginning of the study. In 10 of the 20
patients who developed acute coronary events, measurement
of MCSF was performed on re-admission to the hospital.
The mean plasma concentration of MCSF was 1,234 6
477 pg/ml, which correlated significantly with the concen-
tration of MCSF at the start of the follow-up period (r 5
0.66, p 5 0.039). Of the 15 patients who underwent elective
PTCA or CABG, four underwent elective PTCA because
of continued angina. The mean plasma MCSF concentra-
tion at the time of re-admission in this group of patients was
higher than that at the start of the follow-up period,
although the difference did not reach statistical significance
(1,146 6 215 vs. 727 6 370 pg/ml, p 5 0.16).
Predictors of cardiac events. Based on univariate analysis
using the Cox hazards regression model, seven factors
were found to be related to the development of acute
coronary events (Table 5): 1) plasma MCSF concentration
$950 pg/ml; 2) presence of multivessel CAD; 3) presence
of UA on hospital admission; 4) LVEF ,40%; 5) lipopro-
tein (a) concentration $40 mg/dl; 6) HDL cholesterol
concentration ,1.0 mmol/liter; and 7) no lipid-lowering
drug therapy use. Based on multiple regression analysis
(Table 5), a plasma MCSF concentration $950 pg/ml was
an independent risk factor for an unfavorable outcome, with
an increased relative risk of acute coronary events (RR 23.7,
95% CI 5.4 to 103.8). Furthermore, multivessel CAD and
a low LVEF were also independent predictors of acute
coronary events (RR 6.8, 95% CI 1.9 to 23.9 and RR 3.1,
95% CI 1.1 to 8.7, respectively).
Clinical features of patients with MCSF concentrations
>950 pg/ml. The cumulative two-year cardiac event-free
rate in patients with an MCSF concentration $950 pg/ml
is significantly lower than that in patients with an MCSF
concentration ,950 pg/ml (p , 0.001) (Fig. 3). The
clinical characteristics of patients with an MCSF con-
centration $950 pg/ml are summarized in Table 6.
Those patients with a high plasma MCSF concentration
$950 pg/ml were significantly older and had a higher
incidence of UA and a lower plasma HDL cholesterol
concentration as compared with those patients with a
plasma MCSF concentration ,950 pg/ml.
DISCUSSION
We quantified the circulating MCSF concentration and
assessed its relation with the development of acute coronary
events in patients with angina pectoris. The results demon-
strate that the plasma MCSF concentration in patients with
UA was significantly higher than that in patients with SA.
Furthermore, the greater the extent of CAD, the greater the
circulating MCSF concentration.
MCSF concentration in patients with UA and SA. In the
present study, the plasma MCSF concentration in patients
with UA was significantly higher than that in patients with
SA. The results are consistent with findings from previous
reports (15). Furthermore, Moreno and other investigators
(8–10,16,17) demonstrated that there is a significantly
greater amount of macrophage-rich plaque in patients with
UA or restenosis after PTCA than in patients with SA or no
restenosis after PTCA. In these studies, there are greater
amounts of thrombi and inflammatory macrophages in
primary atherosclerotic plaques in patients with acute cor-
onary syndromes than in patients with SA. Further, the
Figure 1. Circulating MCSF concentrations in patients with UA,
patients with SA and control subjects. ***p , 0.001 (by post hoc
analysis).
Figure 2. Changes in the circulating MCSF concentration in
patients with CAD and in control subjects. The plasma MCSF
concentration increased in proportion to the number of diseased
coronary arteries, giving a significant positive correlation between
the MCSF concentration and the number of diseased coronary
arteries (r 5 0.328, p , 0.001). Co 5 control subjects.
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macrophage and thrombus contents are correlated. Finally,
a greater amount of tissue factor is present in primary
coronary plaque tissue (often macrophage-rich or thrombi-
containing plaque). Macrophages may be involved in resten-
osis because of their capacity to express numerous growth
factors, cytokines (11) and metalloproteinases (18–20). In
addition, restenosis after PTCA is associated with mono-
cyte activation at the time of PTCA (21). The mechanisms
responsible for macrophage involvement in cardiac events
may include thrombus organization, smooth muscle cell
migration and proliferation and constrictive scarring of the
adventitia. Previous reports have demonstrated that smooth
muscle cells express granulocyte-macrophage colony–
stimulating factor in both normal and atherosclerotic hu-
man coronary arteries (22). These results suggest that
MCSF is involved in the progression of coronary athero-
sclerosis and in the destabilization of atheromatous plaque.
In the present study, most of the patients with high
Table 2. Clinical Features of Patients With Coronary Artery Disease
Extent of CAD
Zero
Vessels
(n 5 37)
One
Vessel
(n 5 51)
Two
Vessels
(n 5 27)
Three
Vessels
(n 5 27) p Value
Age (yrs) 59 6 8 62 6 9 63 6 9 64 6 8 0.08
Men 6 (70%) 40 (78%) 24 (89%) 22 (81%) 0.34
Previous MI 2 (5%) 24 (47%) 7 (26%) 16 (59%) ,0.001
LDL-c (mmol/liter) 3.0 6 0.8 3.2 6 0.7 3.1 6 1.3 3.2 6 0.7 0.70
HDL-c (mmol/liter) 1.3 6 0.3 1.2 6 0.3 1.0 6 0.2 1.2 6 0.2 0.01
VLDL-c (mg/dl) 193 6 113 246 6 128 197 6 109 196 6 117 0.11
Lipoprotein (a) (mg/dl) 20 6 18 23 6 20 32 6 31 34 6 30 0.05
Coronary risk factors
Hypertension (%) 19 (51%) 28 (55%) 19 (70%) 14 (52%) 0.42
Diabetes (%) 3 (8%) 17 (33%) 9 (33%) 19 (70%) ,0.001
Hyperlipidemia (%) 18 (49%) 42 (82%) 20 (74%) 16 (59%) 0.01
Smoking (%) 15 (41%) 22 (43%) 15 (56%) 16 (59%) 0.35
Therapy
PTCA (%) 2 (5%) 24 (47%) 18 (67%) 17 (63%) ,0.001
Oral nitrates (%) 15 (41%) 36 (71%) 20 (74%) 18 (67%) 0.01
Calcium antagonists (%) 27 (73%) 35 (69%) 18 (67%) 18 (67%) 0.94
Beta-blockers (%) 1 (3%) 10 (20%) 7 (26%) 3 (11%) 0.04
ACE inhibitors (%) 7 (19%) 18 (35%) 13 (48%) 12 (44%) 0.06
Lipid-lowering drugs (%) 8 (22%) 26 (51%) 10 (37%) 8 (30%) 0.03
Aspirin (%) 4 (11%) 23 (45%) 16 (59%) 21 (78%) ,0.001
Antiplatelet agents (%) 6 (16%) 27 (53%) 17 (63%) 16 (59%) ,0.001
Acute CE (%) 0 3 (6%) 8 (30%) 9 (33%) ,0.001
Data are presented as the mean value 6 SD or number (%) of patients.
CAD 5 coronary artery disease; CE 5 cardiac events; other abbreviations as in Table 1.
Table 3. Atherosclerotic Events and Macrophage Colony–Stimulating Factor Concentrations in Study Patients
Events
No. of
Patients
MCSF-1*
(pg/ml)
No. of
PTCAs†
MCSF-2*
(pg/ml)
Acute coronary events (%) 20 (14%) 1,192 6 232 9 (45%) 1,158 6 239
Cardiac death (%) 0 0
Acute MI (%) 7 (5%) 1,232 6 203 3 (43%) 1,153 6 213
Unstable angina (%) 8 (6%) 1,161 6 229 5 (63%) 1,165 6 302
Emergent PTCA or CABG (%) 5 (3%) 1,186 6 311 1 (20%) 1,140
Elective PTCA or CABG (%) 15 (11%) 803 6 177 8 (53%) 788 6 324
Other atherosclerotic events (%) 4 (3%) 1,088 6 111 0
Cerebrovascular ischemic events (%) 2 (1%) 0
Arteriosclerotic obliteration (%) 2 (1%) 0
None (%) 103 (72%) 690 6 213 44 (43%) 725 6 170
*p , 0.001 in multiple comparisons, using analysis of variance, of patients with acute coronary events, those with elective PTCA or CABG, those with other atherosclerotic events
(only in MCSF-1) and those with none of these conditions. †Number of patients undergoing PTCA at the start of the follow-up period.
CABG 5 coronary artery bypass graft surgery; MCSF-1 5 plasma macrophage colony–stimulating factor concentration in patients with or without coronary events;
MCSF-2 5 plasma macrophage colony–stimulating factor concentration in patients who had PTCA at the start of the follow-up period; other abbreviations as in Table 1.
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plasma MCSF concentrations had acute coronary events.
Eight of these patients had progression of the atheroscle-
rotic lesion within 10 months after PTCA, resulting in
restenosis or total occlusion. The MCSF concentration in
these patients was higher than that in those patients
undergoing elective PTCA. However, we could not deter-
mine the reason for this finding because of differences in
underlying factors. Accordingly, further prospective studies
will be needed to determine the responsible mechanism.
However, the increase in the plasma MCSF concentration
suggests that it may play a part in the progression of
atherosclerotic lesions.
Circulating concentrations of MCSF in CAD. The
present study demonstrated that the plasma MCSF concen-
tration in our study patients had a significant positive
correlation with the extent of CAD. Repeat coronary
arteriography in 20 patients with acute coronary events
demonstrated restenosis or total occlusion after PTCA in
nine patients (45%) during the follow-up period. Moreover,
the progression of significant stenotic lesions in 8 of the 11
remaining patients resulted in coronary events, and the
development of a new stenotic lesion in one patient was
confirmed. In these patients, it is likely that atherosclerotic
progression also occurred in major arteries other than the
coronary arteries. However, such progression was not con-
Figure 3. Cumulative two-year cardiac event-free survival curves
for patients with angina pectoris. The cardiac event-free rate in
patients with an MCSF concentration $950 pg/ml is significantly
lower than that in patients with an MCSF concentration ,950
pg/ml (p , 0.001).
Table 5. Cox Proportional Hazards Regression Analysis for the Predictors of Acute Coronary
Events
Variables
Univariate Analysis Multivariate Analysis
p Value RR (95% CI) p Value RR (95% CI)
Age 0.06 1.1 (1.0–1.1) NS NS
Male gender 0.73 0.8 (0.3–2.3) NS NS
Previous MI 0.17 1.8 (0.8–3.9) NS NS
Unstable angina ,0.001 7.9 (2.9–21.7) NS NS
MCSF $ 950 pg/ml ,0.001 34.9 (8.1–151.0) ,0.001 23.7 (5.4–103.8)
Plasma lipid concentration
LDL-c $4 mmol/liters 0.97 1.0 (0.2–4.4) NS NS
VLDL-c $ 250 mg/dl 0.27 0.5 (0.2–1.6) NS NS
HDL-c ,1.0 mmol/liters 0.004 3.6 (1.5–8.8) NS NS
Lipoprotein (a) .40 mg/dl 0.003 3.8 (1.5–9.2) NS NS
Coronary risk factor
Diabetes 0.09 0.4 (0.2–1.2) NS NS
Smoking 0.21 0.6 (0.3–1.3) NS NS
Hyperuricemia 0.59 0.7 (0.3–2.1) NS NS
Hypertension 0.63 0.8 (0.3–2.1) NS NS
Therapy
PTCA 0.07 2.3 (0.9–5.6) NS NS
Nonuse of oral nitrates 0.75 1.2 (0.5–2.9) NS NS
Nonuse of lipid-lowering
drugs
0.05 3.5 (1.0–12.0) NS NS
Nonuse of aspirin 0.07 2.5 (0.9–6.6) NS NS
Nonuse of ACE inhibitors 0.05 2.4 (1.0–5.4) NS NS
Nonuse of beta-blockers 0.24 0.3 (0.1–2.2) NS NS
Nonuse of antiplatelet agents 0.18 1.8 (0.8–4.5) NS NS
Nonuse of calcium antagonists 0.60 0.8 (0.3–2.0) NS NS
CAD (two or three vessels) ,0.001 11.7 (3.4–40.2) 0.003 6.8 (1.9–23.9)
LVEF ,40% 0.002 5.1 (1.8–14.4) 0.037 3.1 (1.1–8.8)
CAD 5 coronary artery disease; CI 5 confidence interval; MCSF 5 macrophage colony–stimulating factor; RR 5 relative risk.
Other abbreviations as in Table 1.
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firmed by peripheral angiography or radiologic imaging.
Therefore, our results are consistent with previous reports
(8,10) and suggest that increases in the circulating MCSF
concentration reflect the activity or progression of athero-
genesis in the coronary arteries of patients with coronary
events. In addition, our results suggest that macrophage
tissue factor expression may be responsible for prolonged
luminal surface thrombogenicity after balloon injury (23).
MCSF and acute coronary events. In the present study,
20 patients with acute coronary events had significantly
higher concentrations of circulating MCSF at the start of
the follow-up period, as compared with those without
coronary events. In 10 of these patients with coronary
events, the circulating MCSF concentration was measured
on re-admission to the hospital and demonstrated an
increase in the MCSF concentration in three patients and a
decrease in seven patients. However, there were no signif-
icant differences in the mean MCSF concentration between
the value at the beginning of the follow-up period and that
at the end point. This suggests that the MCSF concentra-
tion was maintained at a high level during the clinical course
of these 10 patients. In the remaining patients experiencing
cardiac events, however, it was impossible to measure or
assess the circulating MCSF concentration because of dif-
ferences in the time of blood sampling.
The plasma MCSF concentration in the 15 patients who
underwent elective PTCA or CABG during the follow-up
period was higher than that in patients who had not
undergone PTCA at the start of the follow-up period or in
patients who had undergone PTCA at the start of the
follow-up period and had no subsequent cardiac events. The
MCSF concentration in the four patients who underwent
elective PTCA tended to be greater than that at the start of
the follow-up period in all of the patients. This result
suggests that inflammation in the coronary arterial wall is
progressive and leads to the development of acute coronary
syndromes.
Predictive value for cardiac events. Based on the results,
the overall sensitivity of a high MCSF concentration
($950 pg/ml) for predicting cardiac events at six months is
88.9%, and the specificity of a low MCSF concentration
(,950 pg/ml) for predicting cardiac events at six months is
84.3%. Therefore, the accuracy of a high MCSF concen-
tration for predicting cardiac events is 85%. However, we
Table 6. Clinical Features of Patients With a Macrophage Colony–Stimulating Factor (MCSF)
Concentration $950 pg/ml or ,950 pg/ml
Variables
MCSF Concentration
p Value
>950 (pg/ml)
(n 5 35)
<950 (pg/ml)
(n 5 107)
Age (years) 65 6 9 61 6 9 0.009
Men 28 (80%) 84 (79%) 0.99
Previous MI 11 (31%) 38 (35%) 0.69
Unstable angina 25 (71%) 20 (19%) ,0.001
Plasma lipid concentration
LDL-c (mmol/liters) 3.2 6 1.2 3.1 6 0.7 0.62
HDL-c (mmol/liters) 1.1 6 0.2 1.3 6 0.4 0.003
Lipoprotein (a) (mg/dl) 31 6 23 24 6 25 0.17
Coronary risk factors
Hyperlipidemia (%) 24 (69%) 72 (67%) 0.99
Hypertension (%) 14 (40%) 48 (45%) 0.69
Diabetes (%) 24 (69%) 70 (65%) 0.84
Hyperuricemia (%) 10 (29%) 24 (22%) 0.50
Smoking (%) 21 (60%) 53 (49%) 0.33
Therapy
PTCA 7 (49%) 44 (41%) 0.56
Oral nitrates (%) 20 (57%) 69 (65%) 0.54
Calcium antagonists (%) 21 (60%) 77 (72%) 0.21
Beta-blockers (%) 2 (6%) 19 (18%) 0.10
ACE inhibitors (%) 18 (51%) 32 (30%) 0.03
Lipid-lowering drugs (%) 9 (26%) 43 (40%) 0.16
Aspirin (%) 20 (57%) 44 (41%) 0.12
Antiplatelet agents (%) 18 (51%) 48 (45%) 0.56
Multivessel disease
Two or three vessels (%) 21 (60%) 33 (31%) 0.003
LVEF (%) 62 6 17% 63 6 14% 0.74
Data are presented as the mean value 6 SD or number (%) of patients.
Abbreviations as in Table 1.
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could not evaluate the predictive value of a high MCSF
concentration for determining restenosis or occlusion in
patients with PTCA, because the patients who underwent
PTCA at the start of the follow-up period did not have a
second coronary arteriogram.
High concentrations of MCSF in patients without car-
diac events. In the present study, there were 13 patients
with a high concentration of MCSF ($950 pg/ml) but who
had no acute coronary events. Of these patients, two had
diabetes mellitus, one had hypertension, one had hyperlip-
idemia and four had diabetes mellitus complicated by
hyperlipidemia. However, only three patients had poorly
controlled diabetes mellitus and subsequently were treated
with oral agents. Liu (24) and Saini (25) and colleagues have
demonstrated that hyperglycemia reduces macrophage
phagocytic function and enhances the growth response of
macrophages to MCSF. Thus, the effect of circulating
MCSF in patients with diabetes mellitus might be enhanced
by continuous hyperglycemia. With respect to hyperlipid-
emia, there is a tendency for MCSF to decrease after
therapy with lipid-lowering agents. However, there were
several patients with hyperlipidemia and high MCSF con-
centrations whose MCSF value did not decrease despite a
decrease in lipid concentrations with lipid-lowering agents.
The lack of a decrease in the MCSF concentration could
not be clarified in this study.
In the other patients, the cause of a high MCSF
concentration is unknown. None of the patients had neo-
plasms, infectious diseases or collagen vascular diseases
during the follow-up period. Although a few of these
patients had hyperuricemia or obesity, the mean uric acid
concentration and body mass index were similar to those
values of patients with normal concentrations of MCSF. A
few of the patients with a high MCSF concentration had
similar values two to four months later (data not presented),
without increases in markers of inflammation, such as
C-reactive protein. Although it is possible that macroangi-
opathy was present, further studies are necessary to deter-
mine the cause of unexplained increases in MCSF.
Study limitations. Although the present study showed that
the circulating concentration of MCSF can predict future
coronary events, the measurement of circulating MCSF is
influenced by aging, diet, gender and medications. Several
investigators have demonstrated the effect of aspirin or
antiplatelet agents on the MCSF concentration (14). The
MCSF promotes the ability of macrophages to phagocytose
oxidized LDL generated by eating. We confirmed circadian
variations in the circulating MCSF concentration in several
patients enrolled in the present study, with a peak in the
concentration at about midnight and a trough in the
concentration at noon (data not presented). In addition,
there are no reports on the day-to-day variation in circulat-
ing MCSF concentrations. Therefore, further evaluation of
circadian variations and day-to-day variations in the MCSF
concentration are needed. There were only 10 patients with
coronary events in the present study, making the compari-
son of MCSF concentrations difficult. The period before
acute coronary events in these patients was relatively short
(about four months), resulting in minimal variability. How-
ever, we could not determine whether the increase in the
circulating MCSF concentration was constant in patients
with coronary events.
The study design did not allow us to determine whether
the increase of MCSF in patients with angina pectoris is a
cause or consequence of plaque instability. The increase in
MCSF in the systemic circulation may simply be a reflection
of events occurring in the coronary circulation. However,
although the clinical manifestations of acute coronary syn-
dromes are determined at the level of the coronary circula-
tion, the demonstration of a systemic inflammatory response
supports the hypothesis that systemic factors may contribute
to plaque instability.
Conclusions. The results of the present study demonstrate
that the concentration of circulating MCSF is an indepen-
dent predictor of near future coronary events in patients
with angina pectoris. However, further studies are required
to establish the mechanistic relations between the circulat-
ing MCSF concentrations and the development of coronary
events and to investigate whether a time-dependent inflam-
matory process occurs, at least in patients with increased
circulating concentrations of MCSF.
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